Journal article
Identification of blood lipid markers of docetaxel treatment in prostate cancer patients
Scientific reports, Vol.14(1), 22069
09/27/2024
DOI: 10.1038/s41598-024-73074-8
PMCID: PMC11436995
PMID: 39333185
Abstract
Docetaxel is commonly used for treatment of castration-resistant prostate cancer. Unfortunately, many prostate cancer patients develop resistance to docetaxel. Clinical markers less invasive than biopsies, such as blood samples, would be ideal for monitoring and predicting patient treatment outcomes to docetaxel. Lipid alterations are often associated with the progression of many cancers, including prostate cancer. This study investigated the use of lipids from whole blood as clinical markers for docetaxel resistance in a small cohort of patients with prostate cancer. Qualitative lipidomics was performed by liquid chromatography-tandem mass spectrometry to assess the lipid composition of prostate cancer cells exposed to docetaxel as well as whole blood from prostate cancer patients before, during and after docetaxel treatment. Three patients had castration resistant prostate cancer, three had castration sensitive prostate cancer, and four had
de novo
prostate cancer during the extent of the study. Mean decrease accuracy and classical univariate receiving operating characteristic curve analyses were performed to identify potential biomarkers. In total, 245 and 221 altered lipids were identified from a second stage of mass spectrometry analysis of prostate cancer cells and clinical blood samples, respectively. Both models indicated that docetaxel treatment altered ether-linked phosphatidylcholines, lysophosphatidylcholine, diacylglycerols, ceramides, hexosylceramides, and sphingomyelins. The results also indicated several lipid changes were associated with sphingolipid signaling and metabolism, and glycerophospholipid metabolism. Collectively, these data suggest the potential usage of identified lipid species as indicators of docetaxel resistance in prostate cancer.
Details
- Title: Subtitle
- Identification of blood lipid markers of docetaxel treatment in prostate cancer patients
- Creators
- Morgan C. Finnerty - University of GeorgiaFranklin E. Leach - University of GeorgiaYousef Zakharia - University of IowaKenneth G. Nepple - University of IowaMichael G. Bartlett - University of GeorgiaMichael D. Henry - University of IowaBrian S. Cummings - University of Georgia
- Resource Type
- Journal article
- Publication Details
- Scientific reports, Vol.14(1), 22069
- DOI
- 10.1038/s41598-024-73074-8
- PMID
- 39333185
- PMCID
- PMC11436995
- NLM abbreviation
- Sci Rep
- ISSN
- 2045-2322
- eISSN
- 2045-2322
- Publisher
- Nature Publishing Group UK
- Grant note
- National Institutes of Health: 201103721
The authors would like to thank Francesca Nugent of the Holden Comprehensive Cancer Center Tissue Procurement Core, which manages the University of Iowa Biobank (IRB#201103721), for services provided related to acquisition of study specimens and/or data. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Biospecimen and clinical data were obtained through the University of Iowa Genito-Urologic Molecular Epidemiology Resource (GU-MER), Institutional Review Board-approved biospecimen repositories.
- Language
- English
- Date published
- 09/27/2024
- Academic Unit
- Molecular Physiology and Biophysics; Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Radiation Oncology; Urology; Internal Medicine
- Record Identifier
- 9984720160202771
Metrics
2 Record Views